Shared on 04 Nov 25

Fair value Increased 2.87%

Danaher’s fair value estimate has increased to $254.40 from $247.30. This reflects analysts’ view that while growth forecasts are now more gradual and discount rates slightly higher, the stock’s premium valuation still prices in a slow recovery and ongoing sector uncertainties.

Shared on 21 Oct 25

Fair value Increased 1.15%

Analysts have marginally raised their fair value estimate for Danaher to $247.30 from $244.50, citing improved profit margins and earnings quality. However, near-term growth expectations remain tempered by ongoing market uncertainties.

Shared on 11 Sep 25

Fair value Decreased 0.41%

Danaher’s consensus price target saw a marginal downward revision to $244.50 as analysts incorporate more conservative near-term estimates amid continued sector weakness and tempered recovery expectations, despite steady long-term fundamentals. Analyst Commentary Bearish analysts are lowering price targets due to "more realistic" multiples and sector-wide weakness in Life Sciences Tools and Diagnostics, with a cautious view on near-term healthcare stock performance.